Winton Group’s Ascendis Pharma A/S ASND Stock Holding History

Winton Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,349	Closed	-$374K	–	1024
2021 Q3	$374K	Buy	+2,349	New	+$321K	0.02%	1001
2021 Q2	–	Sell	-1,623	Closed	-$209K	–	1418
2021 Q1	$209K	Buy	1,623 +373	+30%	+$56.7K	0.01%	1268
2020 Q4	$208K	Sell	1,250 -2,193	-64%	-$363K	0.02%	1178
2020 Q3	$531K	Buy	+3,443	New	+$495K	0.02%	1090

Other funds holding ASND

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Winton Group's ASND Position: Q4 2021 in Review

Winton Group sold out of Ascendis Pharma A/S (ASND) in Q4 2021, closing a stake of 2,349 shares — an estimated $374K sold.

Winton Group first reported a position in ASND in Q3 2020 and held it in 4 quarters. The position peaked at $531K in Q3 2020. 172 funds tracked by Wall St. Rank hold ASND as of Q4 2021.

Winton Group reported no remaining Ascendis Pharma A/S position as of Q4 2021 after selling out during the quarter.
Winton Group sold 2,349 Ascendis Pharma A/S shares in Q4 2021, an estimated $374K.
Winton Group first reported a position in Ascendis Pharma A/S in Q3 2020 and held it in 4 quarters.
Winton Group's Ascendis Pharma A/S position peaked at $531K in Q3 2020.
172 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2021.

Based on Winton Group's 13F filing for Q4 2021, filed 10 Feb 2022.